Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelira Therapeutics ( (AU:ZLD) ) has shared an announcement.
Zelira Therapeutics has announced a non-dilutive R&D loan facility secured against its anticipated R&D tax incentive rebate for FY25, which will be used to advance the HOPE® SPV clinical trial and general working capital. Additionally, the company’s directors have provided unsecured loan notes to support operations. The company is making significant progress in its FDA program for the HOPE® clinical trial, with plans to launch Phase 1 trials for its HOPE® 1 Phelan McDermid Syndrome program. This development is part of Zelira’s strategy to bring effective cannabinoid-based therapies to market, targeting ultra-rare genetic conditions and improving patient outcomes.
The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Ltd is a global leader in the development and commercialization of clinically validated cannabinoid-based medicines. The company focuses on innovative therapies to improve the quality of life for patients, particularly those with Autism Spectrum Disorder (ASD) and related conditions.
YTD Price Performance: -42.74%
Average Trading Volume: 4,882
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.22M
For detailed information about ZLD stock, go to TipRanks’ Stock Analysis page.